ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -45 مورد

Terazosin: Pediatric drug information

Terazosin: Pediatric drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Terazosin: Drug information" and "Terazosin: Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Tezruly
Brand Names: Canada
  • APO-Terazosin;
  • PMS-Terazosin;
  • TEVA-Terazosin
Therapeutic Category
  • Alpha-Adrenergic Blocking Agent, Oral;
  • Antihypertensive Agent;
  • Vasodilator
Dosing: Pediatric
Hypertension

Hypertension:

Note: Current pediatric blood pressure guidelines do not include terazosin for the management of pediatric hypertension; other agents are preferred (Ref).

Children and Adolescents: Limited data available: Oral: Initial: 1 mg once daily typically administered at bedtime; slowly increase dose to achieve desired blood pressure as tolerated; maximum daily dose: 20 mg/day (Ref). Note: If drug is discontinued for longer than several days, consider beginning with initial dose and retitrate as needed due to risk of postural hypotension and syncope.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Altered kidney function: There are no pediatric-specific dosage recommendations. Based on experience in adult patients, no dosage adjustment is likely necessary.

Hemodialysis: Based on adult information, 10% dialyzable; supplemental dose not necessary.

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Adult

(For additional information see "Terazosin: Drug information")

Note: If therapy is discontinued for several days or more, consider beginning with initial dose and retitrate as needed, due to risk of orthostatic hypotension.

Benign prostatic hyperplasia

Benign prostatic hyperplasia (monotherapy or combination therapy):

Note : In patients with moderate to severe predominant storage lower urinary tract symptoms, use in combination with beta-3 agonist or anticholinergic agent. In patients with a significantly enlarged prostate (prostate volume >30 mL, prostate-specific antigen >1.5 ng/mL, or palpable prostate enlargement on digital rectal exam), use in combination with 5-alpha reductase inhibitor (Ref).

Oral: Initial: 1 mg once daily at bedtime; titrate slowly every few weeks (eg, to 2 mg, then 5 mg, then 10 mg) based on response and tolerability; usual dose: 10 mg once daily; if no response after 4 to 6 weeks of 10 mg once daily, may increase to a maximum dose of 20 mg once daily.

Hypertension

Hypertension (alternative agent):

Note: Not recommended for initial management, but may be considered as additional therapy for resistant hypertension in patients who do not respond adequately to combination therapy with preferred agents (Ref).

Oral: Initial: 1 mg once daily; titrate gradually, as needed, based on response and tolerability up to 20 mg/day in 1 or 2 divided doses (Ref). Note: Administration at bedtime may help limit orthostasis.

Ureteral stone(s) expulsion

Ureteral stone(s) expulsion (off-label use):

Note: Consider for use in patients with ureteral stones >5 and ≤10 mm (Ref). Although most evidence exists for distal ureteral stones, given the low side effect profile of alpha-blockers, may consider use in patients with stones in any location of ureter (Ref). Additionally, may consider for use after shock wave lithotripsy to help pass stone fragments (Ref). A uroselective alpha blocker (eg, tamsulosin) may be preferred to decrease risk of hypotension (Ref).

Oral: 2 to 5 mg once daily at bedtime until stone passage or for up to 4 weeks (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: No dosage adjustment necessary for any degree of kidney dysfunction (Ref).

Hemodialysis, intermittent (thrice weekly): Dialyzable (~10%) (Ref): No supplemental dose or dosage adjustment necessary (Ref).

Peritoneal dialysis: Unlikely to be significantly dialyzed (highly protein bound): No dosage adjustment necessary (Ref).

CRRT: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (Ref).

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.

>10%: Nervous system: Asthenia (≤11%), dizziness (9% to 19%), fatigue (≤11%), lassitude (≤11%)

1% to 10%:

Cardiovascular: Orthostatic hypotension (1% to 5%), palpitations (4%), peripheral edema (6%), tachycardia (2%)

Gastrointestinal: Nausea (2% to 4%)

Genitourinary: Impotence (2%)

Nervous system: Drowsiness (4% to 5%), paresthesia (3%), vertigo (1%)

Neuromuscular & skeletal: Back pain (2%), limb pain (4%)

Ophthalmic: Amblyopia (≤1%), blurred vision (≤2%)

Respiratory: Dyspnea (2% to 3%), nasal congestion (≤6%), rhinitis (≤2%), sinusitis (3%)

<1%:

Cardiovascular: Syncope

Endocrine & metabolic: Weight gain

Frequency not defined:

Nervous system: Headache

Miscellaneous: Fever

Postmarketing:

Cardiovascular: Atrial fibrillation

Dermatologic: Acute generalized exanthematous pustulosis (Speck 2008), lichenoid eruption (Koh 2008)

Genitourinary: Priapism

Hematologic & oncologic: Thrombocytopenia

Hypersensitivity: Anaphylaxis, hypersensitivity reaction

Ophthalmic: Intraoperative floppy iris syndrome (Venkatesh 2007)

Contraindications

Hypersensitivity to terazosin or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).

• Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha1-blockers; there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery. May require modifications to surgical technique.

• Orthostatic hypotension/syncope: May cause significant orthostatic hypotension and syncope, especially with first dose or first few days of therapy; anticipate a similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, or if another antihypertensive drug (particularly vasodilators) or a PDE-5 inhibitor is introduced.

• Priapism: Priapism has been associated with use (rarely); seek immediate medical assistance for erections lasting longer than 4 hours.

Disease-related concerns:

• Heart failure: In a scientific statement from the American Heart Association, terazosin has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).

Other warning/precautions:

• Appropriate use: BPH: Rule out prostatic carcinoma before beginning therapy (many symptoms of BPH and prostate cancer are similar).

Product Availability

Tezruly 1 mg/mL oral solution: FDA approved July 2024; anticipated availability currently unknown. Information pertaining to this product within the monograph is pending revision. Tezruly is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia and management of hypertension. Consult the prescribing information for additional information.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Generic: 1 mg, 2 mg, 5 mg, 10 mg

Solution, Oral, as hydrochloride:

Tezruly: 1 mg/mL (150 mL) [contains methylparaben, propylparaben; cherry flavor]

Generic Equivalent Available: US

May be product dependent

Pricing: US

Capsules (Terazosin HCl Oral)

1 mg (per each): $1.61

2 mg (per each): $1.61

5 mg (per each): $1.61

10 mg (per each): $1.61

Solution (Tezruly Oral)

1 mg/mL (per mL): $3.86

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Generic: 1 mg, 2 mg, 5 mg, 10 mg

Administration: Pediatric

Oral: Administer without regard to meals at the same time each day.

Administration: Adult

Oral: Administer at the same time each day.

Storage/Stability

Store at 20°C to 25°C (68°F to 77°F); protect from light and moisture.

Use

Treatment of benign prostate hyperplasia (BPH) (FDA approved in adults); treatment of hypertension alone or in combination with other agents, such as diuretics or beta-blockers (FDA approved in adults).

Medication Safety Issues
Older Adult: High-Risk Medication:

Beers Criteria: Terazosin is identified in the Beers Criteria as a potentially inappropriate medication in patients 65 years and older due to its high risk of orthostatic hypotension. Avoid use for hypertension treatment (alternative agents have superior risk:benefit profiles) (Beers Criteria [AGS 2023]).

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

Alpha-/Beta-Agonists: Alpha1-Blockers may decrease therapeutic effects of Alpha-/Beta-Agonists. Risk C: Monitor

Alpha1-Blockers: May increase antihypertensive effects of Alpha1-Blockers. Risk X: Avoid

Amifostine: Blood Pressure Lowering Agents may increase hypotensive effects of Amifostine. Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine. Risk D: Consider Therapy Modification

Amphetamines: May decrease antihypertensive effects of Antihypertensive Agents. Risk C: Monitor

Antihypertensive Agents: May increase hypotensive effects of Terazosin. Risk C: Monitor

Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may increase hypotensive effects of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor

Arginine: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Barbiturates: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Benperidol: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Brigatinib: May decrease antihypertensive effects of Antihypertensive Agents. Brigatinib may increase bradycardic effects of Antihypertensive Agents. Risk C: Monitor

Brimonidine (Topical): May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Bromperidol: May decrease hypotensive effects of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may increase hypotensive effects of Bromperidol. Risk X: Avoid

Dapoxetine: May increase orthostatic hypotensive effects of Alpha1-Blockers. Risk C: Monitor

Dexmethylphenidate: May decrease therapeutic effects of Antihypertensive Agents. Risk C: Monitor

Diazoxide: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

DULoxetine: Blood Pressure Lowering Agents may increase hypotensive effects of DULoxetine. Risk C: Monitor

Flunarizine: May increase therapeutic effects of Antihypertensive Agents. Risk C: Monitor

Herbal Products with Blood Pressure Increasing Effects: May decrease antihypertensive effects of Antihypertensive Agents. Risk C: Monitor

Herbal Products with Blood Pressure Lowering Effects: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Hypotension-Associated Agents: Blood Pressure Lowering Agents may increase hypotensive effects of Hypotension-Associated Agents. Risk C: Monitor

Iloperidone: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Isocarboxazid: May increase antihypertensive effects of Antihypertensive Agents. Risk X: Avoid

Levodopa-Foslevodopa: Blood Pressure Lowering Agents may increase hypotensive effects of Levodopa-Foslevodopa. Risk C: Monitor

Levomethadone: May increase hypotensive effects of Alpha1-Blockers (Nonselective). Risk C: Monitor

Loop Diuretics: May increase hypotensive effects of Antihypertensive Agents. Risk C: Monitor

Lormetazepam: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Metergoline: May decrease antihypertensive effects of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may increase orthostatic hypotensive effects of Metergoline. Risk C: Monitor

Methylphenidate: May decrease antihypertensive effects of Antihypertensive Agents. Risk C: Monitor

Midodrine: Alpha1-Blockers (Nonselective) may decrease therapeutic effects of Midodrine. Risk C: Monitor

Molsidomine: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Nicorandil: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Nitroprusside: Blood Pressure Lowering Agents may increase hypotensive effects of Nitroprusside. Risk C: Monitor

Obinutuzumab: May increase hypotensive effects of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Risk D: Consider Therapy Modification

Pentoxifylline: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Perazine: May increase hypotensive effects of Antihypertensive Agents. Risk C: Monitor

Phenylephrine (Systemic): Alpha1-Blockers may decrease vasoconstricting effects of Phenylephrine (Systemic). Risk C: Monitor

Pholcodine: Blood Pressure Lowering Agents may increase hypotensive effects of Pholcodine. Risk C: Monitor

Phosphodiesterase 5 Inhibitors: May increase hypotensive effects of Alpha1-Blockers (Nonselective). Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended. Risk D: Consider Therapy Modification

Prostacyclin Analogues: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Quinagolide: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Rilmenidine: Alpha1-Blockers may increase hypotensive effects of Rilmenidine. Risk C: Monitor

Reproductive Considerations

Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. Terazosin is not considered a preferred agent for use in pregnant patients; consider transitioning to a preferred agent in patients planning to become pregnant (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).

Pregnancy Considerations

Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).

Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of chronic hypertension during pregnancy is indicated, agents other than terazosin may be preferred (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]).

Although alpha-blockers may be used to facilitate ureteral stone expulsion, treatments other than terazosin are preferred if stone removal is needed during pregnancy (AUA/ES [Assimos 2016a]; Juliebø-Jones 2022; Lee 2021; Lloyd 2016).

Monitoring Parameters

Standing and sitting/supine blood pressure, especially 2 to 3 hours after the initial dose, then regularly during therapy.

Mechanism of Action

Alpha1-specific blocking agent with minimal alpha2 effects; this allows peripheral postsynaptic blockade, with the resultant decrease in arterial tone, while preserving the negative feedback loop which is mediated by the peripheral presynaptic alpha2-receptors; terazosin relaxes the smooth muscle of the bladder neck, thus reducing bladder outlet obstruction

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Antihypertensive effect: 15 minutes; Peak effect: Antihypertensive effect: 2 to 3 hours

Duration of action: Antihypertensive effect: 24 hours

Absorption: Rapid and complete

Protein binding: 90% to 94%

Metabolism: Hepatic; minimal first-pass

Half-life elimination: ~12 hours

Time to peak, plasma: ~1 hour; delayed ~40 minutes with food

Excretion: Feces (~60%, ~20% as unchanged drug); urine (~40%, ~10% as unchanged drug)

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Older adult: Plasma clearance was decreased by 31.7% and half-life was 14 hours in patients ≥70 years.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Apo terazosin | Itrin | Terazosin;
  • (AR) Argentina: Andrin | Benaprost | Blavin | Comprimix | Eglidon | Flumarc | Fosfomik | Geriprost | Isontyn | Panaprost plb | Proxatan | Terazosina northia | Terazosina Vannier | Viblan;
  • (AT) Austria: Terazosin | Terazosin Alternova | Terazosin arcana | Terazosin ratiopharm | Urocard | Uroflo | Vicard;
  • (AU) Australia: Hytrin;
  • (BD) Bangladesh: Hytrin | Prostol | Rosyn | Terazon;
  • (BE) Belgium: Hytrin | Terasosine | Terazosab | Terazosabb | Terazosine eurogenerics | Terazosine merck-generics | Terazosine ratiopharm | Uro-hytrin;
  • (BF) Burkina Faso: Xeliprost;
  • (BR) Brazil: Adecur | Cloridrato de terazosina | Hytrin;
  • (CH) Switzerland: Hytrin bph;
  • (CI) Côte d'Ivoire: Xeliprost;
  • (CL) Chile: Adecur | Hytrin;
  • (CN) China: Biaolin | Gao te ling | Hytrin | Li shan | Lie gao | Luo di er | Ma sha ni | Man xin lin | Shi ai te | Tai le | Terazosin | Yue ke | Zheng shu;
  • (CO) Colombia: Hytrin | Terazosina | Tructum;
  • (CZ) Czech Republic: Hytrin | Kornam;
  • (DE) Germany: Flotrin | Flotrin max | Flotrin pro | Flotrin start | Flotrin uro | Heitrin | Hytrin | Tera | Tera tad | Terablock | Teranar | Teranar init | Terazid | Terazoflo | Terazosin | Terazosin - 1A pharma | Terazosin Acis | Terazosin al | Terazosin Aristo | Terazosin Awd | Terazosin CT | Terazosin Hexal | Terazosin ratiopharm | Terazosin stada | Terazosin Start | Terazosin uropharm;
  • (DO) Dominican Republic: Hytrin | Terasin | Tezosyn | Tiflox;
  • (EC) Ecuador: Centrax | Hytrin | Terasin;
  • (EG) Egypt: Itrin | Prostasin | Teracin | Terazin;
  • (ES) Spain: Alfaprost | Deflox | Magnurol | Sutif | Teraumon | Terazosina alter | Terazosina Cinfa | Terazosina kern | Terazosina mabo | Terazosina Normon | Terazosina qualix | Terazosina rubio | Terazosina Teva | Zayasel;
  • (FR) France: Dysalfa | Hytrine | Terazosine Biogaran | Terazosine merck | Terazosine ratiopharm | Terazosine teva;
  • (GB) United Kingdom: Hytrin | Hytrin bph | Terazosin | Terazosin arrow | Terazosin cox | Terazosin Focus | Terazosin kent | Terazosin zanza;
  • (GR) Greece: Hytrin;
  • (HK) Hong Kong: Apo terazosin | Hytrin | Kozosin | Pms-terazosin | Teradrin | Terapress | Terasin | Terazo | Terazosin | Terazosin Teva;
  • (HU) Hungary: Hyron | Hytrin | Kornam | Setegis | Terstat;
  • (ID) Indonesia: Hytrin | Hytroz | Terazosin;
  • (IE) Ireland: Benph | Hytrin | Terazosin;
  • (IL) Israel: Hytrin;
  • (IN) India: Hytrin | Olyster | Teradip | Terakare | Teralfa | Terapress | Teraz | Terrakare | Unoter | Vicard-t | Zytrin;
  • (IT) Italy: Extersin | Ezosina | Ibiprovir | Itrin | Prostatil | Terafluss | Teraprost | Terazosina | Terazosina doc | Terazosina eg | Terazosina mgi | Terazosina sandoz | Terazosina tad pharma | Unoprost | Urodie | Uroflus;
  • (JO) Jordan: Hytrin | Terastat;
  • (JP) Japan: Hytracin | Vasomet nikken;
  • (KR) Korea, Republic of: Anaphen | Auskosin | Basozosin | Biphanti | Hanmi terazosin hcl | Hatra | Hiperin | Hitesin | Hizosin | Hydrin | Hysorin | Hytera | Hytrin | Kup teranex | Neotrin | Neotrine | Newrazosin | Panpress | Protera | Prozosin | Santesin | Telazosin | Teracare | Teradin | Teraforce | Teragen | Teralusin | Teramed | Teramin | Teranin | Teraon | Terapam | Terasan | Terasin | Terasta | Teratin | Teratonin | Terazine | Terazo | Terazol | Terazon | Terazosin | Teresin | Teropine | Teros | Terosin | Terozosin | Tetrin | Tezocin | Tezosin | Tracin | Trasin | Tzc | Unitrin | Urotrin | Vasozosin;
  • (KW) Kuwait: Itrin;
  • (LB) Lebanon: Itrin;
  • (LT) Lithuania: Flotrin pro | Heitrin | Hytrin | Terazosin;
  • (LU) Luxembourg: Hytrin;
  • (LV) Latvia: Hytrin | Teraumon;
  • (MA) Morocco: Terazosine;
  • (MX) Mexico: Adecur | Hytrin | Romaken | Terazosina gi ken.;
  • (MY) Malaysia: Apo terazosin | Conmy | Hytrin | Ralsin;
  • (NL) Netherlands: Hytrin | Terazosine;
  • (NO) Norway: Hytrin | Sinalfa;
  • (NZ) New Zealand: Arrow terazosin | Hytrin | Terazosin;
  • (PA) Panama: Hitrin;
  • (PE) Peru: Adenex | Fazodin | Hytrin | Prostanorm | Prostezosin | Teraliv | Teraprost | Terazosina | Terozosina;
  • (PH) Philippines: Conmy | Hykor | Hytrin | Hyzin | Lotencin | Prostera | Ritemed Terazosin | Terozin;
  • (PK) Pakistan: Hytrin | Hyzosin | Lopros | Rozacin;
  • (PL) Poland: Hytrin | Kornam | Setegis;
  • (PR) Puerto Rico: Hytrin | Terazosin | Terazosin HCL;
  • (PT) Portugal: Hytrin | Terazosina;
  • (PY) Paraguay: Adecur | Andrin | Isontyn | Presoless | Tarnil;
  • (RO) Romania: Hytrin;
  • (RU) Russian Federation: Kornam | Setegis | Terazosin | Terazosin Teva | Terazozin;
  • (SA) Saudi Arabia: Apo terazosin | Itrin | Pms-terazosin;
  • (SE) Sweden: Hytrinex | Sinalfa | Terazosin Alternova | Terazosin Copyfarm | Terazosin Hexal | Terazosin Mylan | Terazosin stada;
  • (SG) Singapore: Apo terazosin | Hytrin | Terasin;
  • (SI) Slovenia: Kornam;
  • (SK) Slovakia: Hytrin | Kornam | Setegis;
  • (TH) Thailand: Hytrin;
  • (TN) Tunisia: Hytrine;
  • (TR) Turkey: Hytrin | Teraumon;
  • (TW) Taiwan: Conmy | Hytrin | Kinzosin | Telowsin | Teradrin | Terasin | Terazosin | Tezopin | Weson;
  • (UA) Ukraine: Kornam | Setegis;
  • (UY) Uruguay: Detrusil | Hytrin | Terina | Zoteran;
  • (VE) Venezuela, Bolivarian Republic of: Adecur | Hytrin;
  • (ZA) South Africa: Hytrin
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. Obstet Gynecol. 2019;133(1):e26-e50. [PubMed 30575676]
  3. Assimos D, Krambeck A, Miller NL, et al. Surgical management of stones: American Urological Association/Endourological Society guideline, PART I. J Urol. 2016a;196(4):1153-1160. doi:10.1016/j.juro.2016.05.090 [PubMed 27238616]
  4. Assimos D, Krambeck A, Miller NL, et al. Surgical management of stones: American Urological Association/Endourological Society guideline, part II. J Urol. 2016b;196(4):1161-1169. doi:10.1016/j.juro.2016.05.091 [PubMed 27238615]
  5. Campschroer T, Zhu X, Vernooij RW, Lock MT. Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database Syst Rev. 2018;4:CD008509. doi:10.1002/14651858.CD008509.pub3 [PubMed 29620795]
  6. Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082 [PubMed 31841131]
  7. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  8. Flynn JT, Kaelber DC, Baker-Smith CM, et al; Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3):e20171904. doi:10.1542/peds.2018-1739 [PubMed 30177515]
  9. Giampaolino P, Della Corte L, Formisano C, et al. Successful management of a third-trimester pregnancy complicated by pheochromocytoma: case report. Gynecol Endocrinol. 2018;34(12):1016-1018. doi:10.1080/09513590.2018.1480712. [PubMed 29890868]
  10. Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. Hypertension. [PubMed 24243703]
  11. Gurbuz MC, Polat H, Canat L, Kilic M, Caskurlu T. Efficacy of three different alpha 1-adrenergic blockers and hyoscine N-butylbromide for distal ureteral stones. Int Braz J Urol. 2011;37(2):195-200. [PubMed 21557836]
  12. Hollingsworth JM, Canales BK, Rogers MA, et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ. 2016;355:i6112. doi:10.1136/bmj.i6112 [PubMed 27908918]
  13. James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) [published online December 18, 2013]. JAMA. [PubMed 24352797]
  14. Juliebø-Jones P, Somani BK, Baug S, Beisland C, Ulvik Ø. Management of kidney stone disease in pregnancy: a practical and evidence-based approach. Curr Urol Rep. 2022;23(11):263-270. doi:10.1007/s11934-022-01112-x [PubMed 36197640]
  15. Jungers P, Ganeval D, Pertuiset N, Chauveau P. Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. Am J Med. 1986;80(5B):94-99. doi:10.1016/0002-9343(86)90860-0 [PubMed 2872815]
  16. Koh MJ, Seah PP, Tay YK, Mancer K. Lichenoid drug eruption to terazosin. Br J Dermatol. 2008;158(2):426-427. doi:10.1111/j.1365-2133.2007.08331.x [PubMed 18047505]
  17. Koski RR, Zufall WH. Efficacy and safety of alpha-blockers for kidney stones in adults. J Pharm Technol. 2018;34(2):54-61. doi:10.1177/8755122517750398 [PubMed 34860948]
  18. Lee MS, Fenstermaker MA, Naoum EE, et al. Management of nephrolithiasis in pregnancy: multi-disciplinary guidelines from an academic medical center. Front Surg. 2021;8:796876. doi:10.3389/fsurg.2021.796876 [PubMed 35028309]
  19. Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I-initial work-up and medical management. J Urol. 2021;206(4):806-817. doi:10.1097/JU.0000000000002183 [PubMed 34384237]
  20. Lloyd GL, Lim A, Hamoui N, Nakada SY, Kielb SJ. The use of medical expulsive therapy during pregnancy: a worldwide perspective among experts. J Endourol. 2016;30(3):354-358. doi:10.1089/end.2015.0587 [PubMed 26482104]
  21. Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. J Obstet Gynaecol Can. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002 [PubMed 35577426]
  22. "Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group," JAMA, 2000, 283(15):1967-75. [PubMed 10789664]
  23. National Heart, Lung, and Blood Institute, “Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,” Clinical Practice Guidelines, 2011, National Institutes of Health. Available at http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf.
  24. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, “The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,” Pediatrics, 2004, 114(2 Suppl 4th report):555-76. [PubMed 15286277]
  25. National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. https://www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.
  26. Oestreich MC, Vernooij RW, Sathianathen NJ, et al. Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults. Cochrane Database Syst Rev. 2020;11(11):CD013393. doi:10.1002/14651858.CD013393.pub2 [PubMed 33179245]
  27. Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in Circulation. 2016;134(12):e261]. Circulation. 2016;134(6):e32-e69. [PubMed 27400984]
  28. Refer to manufacturer's labeling.
  29. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-3241. [PubMed 30165544]
  30. Speck LM, Wilkerson MG, Perri AJ, Kelly BC. Acute generalized exanthematous pustulosis caused by terazosin hydrochloride. J Drugs Dermatol. 2008;7(4):395-397. [PubMed 18459523]
  31. Terazosin hydrochloride [prescribing information]. East Brunswick, NJ: Avet Pharmaceuticals Inc; August 2021.
  32. Terazosin hydrochloride [summary of product characteristics]. Middlesex, UK: Accord Healthcare Limited; December 2017.
  33. Venkatesh R, Veena K, Gupta S, Ravindran RD. Intraoperative floppy iris syndrome associated with terazosin. Indian J Ophthalmol. 2007;55(5):395-396. doi:10.4103/0301-4738.33835 [PubMed 17699957]
  34. Wang CJ, Huang SW, Chang CH. Adjunctive medical therapy with an alpha-1A-specific blocker after shock wave lithotripsy of lower ureteral stones. Urol Int. 2009;82(2):166-169. [PubMed 19322003]
  35. Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16(1):14-26. [PubMed 24341872]
  36. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71(6):1269-1324. doi:10.1161/HYP.0000000000000066 [PubMed 29133354]
Topic 86243 Version 374.0